Abstract
Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.
Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft
Letters in Drug Design & Discovery
Title: Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene
Volume: 1 Issue: 1
Author(s): M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell and R. J. Mairs
Affiliation:
Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft
Abstract: Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.
Export Options
About this article
Cite this article as:
Boyd M., Ross S., Owens J., Hunter D., Babich J., Zalutsky R. M., Hamilton G. T., Bell S. and Mairs J. R., Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene, Letters in Drug Design & Discovery 2004; 1 (1) . https://dx.doi.org/10.2174/1570180043485743
DOI https://dx.doi.org/10.2174/1570180043485743 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Nicotinic Acetylcholine Receptor Interaction with β -Amyloid: Molecular, Cellular, and Physiological Consequences
Current Alzheimer Research Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy
Current Drug Targets Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Alpha-Secretase As a Therapeutic Target
Current Alzheimer Research Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets